biostudies-literatureYao YWest China Hospital of Sichuan University84-91https://www.ebi.ac.uk/biostudies/studies/S-EPMC9849429biostudies-literatureUnknown46(1)<h4>Background</h4>Renal and liver dysfunctions are risk factors for mortality in patients with severe aortic stenosis (AS). Transcatheter aortic valve implantation (TAVI) has the potential to break the vicious cycle between AS and hepatorenal dysfunction by relieving aortic valve obstruction.<h4>Hypothesis</h4>A part of patients can derive hepatorenal function improvement from TAVI, and this noncardiac benefit improves the intermediate-term outcomes.<h4>Methods</h4>We developed this retrospective cohort study in 439 consecutive patients undergoing TAVI and described the dynamic hepatorenal function assessed by model for end-stage liver disease model for end-stage liver disease (MELD)-XI score in subgroups. The endpoint was 2-year all-cause mortality.<h4>Results</h4>Receiver-operating charClinical cardiologyPrognostic value of the dynamic hepatorenal function on intermediate-term mortality in TAVI patients with survival to discharge.PMC9849429CGZH19009Peng YZhu ZLiang YLiu QWei XXiong TMeng WYao YZheng MOu YChen YWei JYang HHe JChen MFeng YChen GChen FLi QZhou WZhou XLi XLi YHe SZhang YfalsePrognostic value of the dynamic hepatorenal function on intermediate-term mortality in TAVI patients with survival to discharge.<h4>Background</h4>Renal and liver dysfunctions are risk factors for mortality in patients with severe aortic stenosis (AS). Transcatheter aortic valve implantation (TAVI) has the potential to break the vicious cycle between AS and hepatorenal dysfunction by relieving aortic valve obstruction.<h4>Hypothesis</h4>A part of patients can derive hepatorenal function improvement from TAVI, and this noncardiac benefit improves the intermediate-term outcomes.<h4>Methods</h4>We developed this retrospective cohort study in 439 consecutive patients undergoing TAVI and described the dynamic hepatorenal function assessed by model for end-stage liver disease model for end-stage liver disease (MELD)-XI score in subgroups. The endpoint was 2-year all-cause mortality.<h4>Results</h4>Receiver-operating char2023-01-01T00:00:00Z2023 Jan2025-04-04T18:53:40.8Z2025-04-04T18:53:40.8ZS-EPMC98494293644841210.1002/clc.23940